The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...

A Phase 2a trial testing foralumab nasal spray in people with nonactive SPMS has dosed the first patients enrolled at Yale MS Center.

Data from the ATLAS research comprises a series of trials that have yielded years of long-term, comprehensive data on safety ...

The current state of treatment for geographic atrophy is marked by two approved therapies that slow GA progression: ...

Mural Oncology's stock plummeted 57% after halting the Phase 3 ARTISTRY-7 trial for nemvaleukin alfa. Click here to read an ...

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its ...

NUZ-001 slowed respiratory declines in ALS patients in a Phase 1 trial, and Neurizon is working to ready it for the HEALEY ...

Soleno Therapeutics has won US Food and Drug Administration (FDA) approval for diazoxide choline – which will be branded as ...

Charles C. Wykoff, MD, PhD, Retinal Consultants of Texas, spoke to the current state of research on revakinagene taroretcel ...

After exploring every nook and cranny that Hulu has to offer in this generous 30-day trial, there are a wide range of subscription options to opt into, from $9.99 a month (with ads) all the way up ...

ZDNET Recommends': What exactly does it mean? ZDNET's recommendations are based on many hours of testing, research, and comparison shopping. We gather data from the best available sources ...

3 The persistence of race as a variable in clinical research is largely a result of its continued use in the United States census. Today, the term “racialised” has become embedded in our lexicon, ...